José A. López-Martín

Efficacy of Pembrolizumab in Patients With Noncolorectal High Microsatellite Instability/Mismatch Repair–Deficient Cancer: Results From the Phase II KEYNOTE-158 Study

Aurélien Marabelle, Dung T. Le, Paolo A. Ascierto et al. · Journal of Clinical Oncology · 2019 · 2.8K citations · Full text

Association of tumour mutational burden with outcomes in patients with advanced solid tumours treated with pembrolizumab: prospective biomarker analysis of the multicohort, open-label, phase 2 KEYNOTE-158 study

Aurélien Marabelle, Marwan Fakih, Juanita Lopez et al. · The Lancet Oncology · 2020 · 2.4K citations · Full text

Nivolumab alone and nivolumab plus ipilimumab in recurrent small-cell lung cancer (CheckMate 032): a multicentre, open-label, phase 1/2 trial

Scott Antonia, José A. López-Martín, Johanna C. Bendell et al. · The Lancet Oncology · 2016 · 1.2K citations · Full text

Medicine, Checkmate 032, Pharmacology +5

Pembrolizumab After Two or More Lines of Previous Therapy in Patients With Recurrent or Metastatic SCLC: Results From the KEYNOTE-028 and KEYNOTE-158 Studies

Hyun Cheol Chung, Sarina A. Piha‐Paul, José A. López-Martín et al. · Journal of Thoracic Oncology · 2019 · 427 citations · Full text

Nivolumab Alone and With Ipilimumab in Previously Treated Metastatic Urothelial Carcinoma: CheckMate 032 Nivolumab 1 mg/kg Plus Ipilimumab 3 mg/kg Expansion Cohort Results

Padmanee Sharma, Arlene O. Siefker‐Radtke, Filippo de Braud et al. · Journal of Clinical Oncology · 2019 · 242 citations · Full text